Key Concepts: While the current diagnostic strategies for PD-L1 checkpoint inhibitors identify some responders well, the majority of patients still need diagnostic approaches that better predict response. PD-L1 IHC remains a valuable tool for predicting patient...
Publications / Posters
Methodology for Designing and Validating Computational Pathology Scores for Immune Cell Clustering in Tumor Biopsy Samples
Key takeaways Understanding the frequency and nature of immune cell clustering is useful in determining patient responses to immunomodulating therapies Flagship’s unique spatial biology services generated a validated computational pathology score that characterized...
Comparison of Multiplexed Imaging Mass Cytometry with Monoplex Immunohistochemistry in FFPE Tissue
Abstract Multiplexed analysis of limited tissue samples can improve our understanding of tumor biology and the tumor microenvironment. Chromogenic and fluorescent multiplexed immunohistochemistry (IHC) approaches are available and offer great insights while conserving...
Computational Analysis of Multiplexed Immunohistochemistry for Understanding Immune Profiles in Clinical Biopsy Samples
Abstract Using immunohistochemistry (IHC) to examine immune infiltrates in tissue biopsy samples to support exploratory investigations for immuno-oncology drug development is critical for understanding the abundance and spatial relationships of different immune cell...
Analysis of Multiplexed Immunotherapy Targets and Secreted Ligands Using Computational Tumor Microenvironment Profiling
Key takeaways The RNAscope® platform enabled duplex chromogenic in situ hybridization (CISH) assay visualization of mRNA targets from multiple cell types and biomarkers Quantification of individual and dual cell positivity within tissue compartments Spatial biology...
Sign up to receive industry and company news, including The Cut Point, Flagship’s quarterly e-newsletter.
Recent Posts
NEWS
Flagship Spotlight: Roberto Gianani, MD
Introduction and BackgroundDr. Roberto Gianani, Chief Medical Officer at Flagship Biosciences, Inc., is a practicing pathologist who is board certified in anatomic pathology, clinical pathology, and pediatric pathology. He is fellowship-trained in surgical pathology...
Flagship Spotlight: Adam Beharry
Introduction and BackgroundAdam Beharry, PhD, is a Flagship scientist who describes his work as applying advanced technical knowledge and critical thinking to expand Flagship’s tissue image analysis in neuromuscular and rare diseases. Adam’s degrees include: BS –...
White Paper: Tissue Image Analysis and Biomarker Assessment Implementation Benefits and ROI
IntroductionThe success of clinical trials is highly dependent on the intricacies of patient recruitment. Other challenges, from the costs of clinical supplies to the specific procedural requirements that can extend physicians’ time, can increase costs. There are also...
EVENTS
Oncology Companion Diagnostics Xchange West Coast
Join Flagship for the Oncology Companion Diagnostics Xchange at hubXchange West. February 6-9, 2023. Attending hubXchange West? Meet with us to discuss how we can partner with you for end-to-end support of your immunotherapy research and development program....
Spatial Biology for Immuno-Oncology Summit 2023
Visit Flagship at the SB-IO Summit.January 17-19, 2023. Attending the inaugural SB-IO Summit? Stop by our booth to discuss how we can partner with you for end-to-end support of your immunotherapy research and development program. AI-powered digital pathology solutions...
ASH 2022
Visit Flagship at ASH | Booth #1015. December 10-13, 2022. Attending ASH 2022? Stop by our booth to discuss how we can partner with you for end-to-end biomarker support. Discover our recently expanded services menu and pick up a map of our favorite New Orleans...